Table 1.
Main characteristics of the included studies.
| Reference | Study design | Population | No(T/C) | Male | Age | DM | HTN | Dyslipidaemia | PCI | Stain | Antiplatelet |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Akodad et al. (25) | Open label | STEMI patients ≤12 h successfully treated with PCI | 44 (23/21) | 78% | 59.9 | 14% | 43% | 36% | 100% | NR | 100% |
| Deftereos et al. (26) | Double blind | STEMI patients ≤12 h from the onset of chest pain | 151 (77/74) | 69% | 58 | 21% | 40% | 52% | 100% | NR | NR |
| Gholoobi et al. (27) | Double blind | NSTEMI patients ≤12 h | 150 (75/75) | 52% | 61.42 | 49% | NR | NR | NR | 98% | 100% |
| Hennessy et al. (28) | Double blind | a type 1 AMI patients within the prior 7 days | 237 (119/118) | 77% | 61 | 22% | 47% | NR | 90% | 96% | 100% |
| Hosseini et al. (29) | Double blind | STEMI patients ≤12 h successfully treated with PCI | 321 (161/160) | 79% | 59 | 0.36 | 0.4 | 0.21 | 100% | NR | NR |
| Mewton et al. (30) | Double blind | patients with a first episode of STEMI referred for PCI, chest pain ≤12 h | 192 (101/91) | 80% | 61 | 13% | 31% | 33% | 100% | 98% | 100% |
| Tardif et al. (31) | Double blind | MI patients within 30 days completed any planned PRPs | 4,745 (2,366/2,379) | 81% | 60.55 | 20% | 51% | NR | 93% | 99% | 99% |
| Wasyanto (24) | Open label | AMI patients | 32 (16/16) | 88% | 55.37 | 22% | 47% | 13% | NR | 100% | NR |
| Reference | Colchicine | Initiation of colchicine | Duration of administration | Time of follow-up | Intervention(s) | Discontinuation (%) | |||||
| Akodad et al. (25) | 1 mg QD | within first day of AMI | 30 days | 30 days | colchicine + conventional treatment vs. conventional treatment | 13% | |||||
| Deftereos et al. (26) | 0.5 mg BD or QD | within 3 days of MI | 5 days | 5 days | colchicine vs. placebo | 15% | |||||
| Gholoobi et al. (27) | 0.5 mg BD or QD | within 5 days of AMI | 30 days | 30 days | colchicine + routine medications vs. placebo + routine medications | NR | |||||
| Hennessy et al. (28) | 0.5 mg QD | within 7 days of AMI | 30 days | 30 days | colchicine vs. placebo | 5% | |||||
| Hosseini et al. (29) | 1-mg oral loading dose, followed by 0.5 mg QD | the first day of MI | until discharge | 1 year | colchicine vs. placebo | 8.6% | |||||
| Mewton et al. (30) | 2-mg oral loading dose, followed by 0.5 mg BD | the first day of MI | 5 days | 3 months | colchicine vs. placebo | NR | |||||
| Tardif et al. (31) | 0.5 mg QD | a mean of 13.5 days after MI | 19.6 months (median) | 22.6 months (median) | colchicine vs. placebo | 18.6% | |||||
| Wasyanto (24) | 0.5 mg QD | patients with AMI | 5 days | 5 days | colchicine vs. placebo | NR |
MI, myocardial infarction; AMI, acute myocardial infarction; DM, diabetes disease; HTN, hypertension; PCI, percutaneous coronary intervention; PRPs, percutaneous revascularization procedures. QD, quaque die. BD, bis in die. The duration of colchicine administration mostly coincided with the follow-up period; if it did not, it has been indicated in the table. Deftereos, S 2015: 2 mg (1.5 mg initially followed by 0.5 mg 1 h later) and continuing with 0.5 mg BD for 5 days; Patients with <60 kg received 0.5 mg QD for 5 days. Gholoobi, A. 2021: patients <75 kg, or creatinine clearance <50 ml/min: 0.5 mg QD for 30 days and patients >75 kg: 0.5 mg BD for 30 day.